Skip to Content

What type of drug is Kymriah (tisagenlecleucel)?

Answers (1)

Official Answer by 10 Oct 2017

Kymriah (tisagenlecleucel) is a chimeric antigen receptor T cell (CAR-T) therapy for use in pediatric and young adult patients (up to age 25) with relapsed or refractory (r/r) B-cell acute lymphoblastic leukemia (ALL).

Kymriah is a genetically-modified autologous T-cell immunotherapy. The therapy is derived from a patient's own white blood cells through a process known as leukapheresis. The white cells are modified genetically to include a new gene that contains a specific protein (a chimeric antigen receptor or CAR) that directs the T-cells to target and kill leukemia cells that have a specific antigen (CD19) on the surface.

Once the cells are modified, they are infused back into the patient to kill the cancer cells. Kymriah is the first FDA-approved cell-based gene therapy in the U.S.

See also:

Votes: +0 free discount card

Further Information

Search for questions

Still looking for answers? Try searching for what you seek or ask your own question.

Frequently Asked Questions

What is the difference between Biktarvy and Descovy?

Posted 13 days ago 1 answerFAQ by

What is the difference between Symdeko and Orkambi?

Posted 13 days ago 1 answerFAQ by